Dr. Rombel has overall strategic and operational responsibility for strategic analysis across all functions of the Discovery, Product Development and Supply (DPDS) organization within Janssen Research & Development, leading the gathering and synthesis of information to inform strategic business recommendations on all therapeutic modalities, from discovery through manufacturing.
Prior to joining Janssen in 2015, Irene was Founder and President of Biomedical Intelligence, a consulting company focused on matters pertaining to science, business and intellectual property. Prior to founding Biomedical Intelligence in 2008, Irene was a senior biotechnology hedge fund analyst, and an Assistant Professor at UT Southwestern Medical Center, Dallas, Texas, where she worked on DNA vaccines and cell-specific targeting.
Irene received her post-doctoral training at UC Berkeley and UC Davis, where she conducted research on the regulation of gene expression at the transcriptional level. She earned her Ph.D. in Biochemistry from the University of Otago, New Zealand, and MBA from Southern Methodist University in Dallas, Texas. In addition, Irene is a registered US patent agent.